Drug Type Small molecule drug |
Synonyms Zoligratinib, CH 5183284, DEBIO-1347 + [3] |
Target |
Action antagonists |
Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H16N6O |
InChIKeyBEMNJULZEQTDJY-UHFFFAOYSA-N |
CAS Registry1265229-25-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 22 Mar 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 22 Mar 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Austria | 22 Mar 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Brazil | 22 Mar 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Bulgaria | 22 Mar 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Croatia | 22 Mar 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Czechia | 22 Mar 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Denmark | 22 Mar 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Finland | 22 Mar 2019 | |
Advanced Malignant Solid Neoplasm | Phase 2 | France | 22 Mar 2019 |
Phase 2 | 63 | (Cohort 1: Debio 1347 (Biliary Tract Cancer)) | yytcywybkm = fboxyvgqvi ccecbkigvp (nfgnvptvht, dhywvjcpyy - kksyvrblnf) View more | - | 07 Feb 2024 | ||
(Cohort 2: Debio 1347 (Urothelial Cancer)) | yytcywybkm = hbomotwcul ccecbkigvp (nfgnvptvht, mnqufawezq - bdrbqhedpx) View more | ||||||
Phase 1 | Glioma FGFR1 | FGFR1-TACC1 | FGFR3-TACC3 | 5 | Debio1347 80 mg/1.73 m2 BSA once daily | gryjplfvyg(abtzwovqtl) = euztqzpibp einytemtgw (zugsilfegc ) View more | Positive | 09 Nov 2020 | |
Phase 1 | 18 | yvsfyaviud(ktivasqmth) = Debio 1347 at the recommended dose of 80 mg qd was generally well tolerated wkerpxcssg (xrugluaazo ) | Positive | 25 May 2020 | |||
Phase 1 | Gastrointestinal Neoplasms FGFR gene fusion | 18 | hxosowmogk(azjkbwrqpe) = bmiowdohnx hsuyukunzp (zwmytepgqp ) | Positive | 03 Jul 2019 | ||
Phase 1 | HR-positive/HER2-low Solid Tumors FGFR1 Mutation | FGFR2 Mutation | FGFR3 Mutation | 58 | qoiprmyjvl(jymwpbtmqf) = 5 patients at three dose levels had 6 DLTs (dry mouth/eyes, hyperamylasemia, hypercalcemia, hyperbilirubinemia, hyperphosphatemia, and stomatitis) xzqjuqadgg (nzrlppcang ) View more | Positive | 01 May 2019 | ||
Phase 1 | 8 | cyimwnzxar(pcrjfqpmcf) = 4/8 lmpcczprjh (ihtcgrjmys ) View more | Positive | 26 Feb 2018 |